Compare PTC & STE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTC | STE |
|---|---|---|
| Founded | 1985 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 25.9B |
| IPO Year | 1989 | 1992 |
| Metric | PTC | STE |
|---|---|---|
| Price | $173.03 | $263.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $207.08 | ★ $268.25 |
| AVG Volume (30 Days) | ★ 912.2K | 674.3K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 0.96% |
| EPS Growth | ★ 94.87 | 59.39 |
| EPS | 6.08 | ★ 6.97 |
| Revenue | $2,739,226,000.00 | ★ $5,702,415,000.00 |
| Revenue This Year | $2.80 | $9.24 |
| Revenue Next Year | $8.31 | $6.30 |
| P/E Ratio | ★ $28.54 | $37.72 |
| Revenue Growth | ★ 19.18 | 7.08 |
| 52 Week Low | $133.38 | $200.98 |
| 52 Week High | $219.69 | $268.60 |
| Indicator | PTC | STE |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 59.06 |
| Support Level | $172.65 | $256.68 |
| Resistance Level | $179.32 | $268.60 |
| Average True Range (ATR) | 3.78 | 4.64 |
| MACD | 1.28 | -0.69 |
| Stochastic Oscillator | 40.08 | 65.59 |
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as augmented reality industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue mostly from North America and Europe.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.